Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

New oral anti-coagulants: Implications for neurosurgery.

Vakharia VN, Tai D, Marcus H, Vakharia NN, Nandi D.

Br J Neurosurg. 2015 Apr;29(2):182-8. doi: 10.3109/02688697.2014.997667. Epub 2015 Jan 29.

PMID:
25633803
2.

The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.

Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA.

Am J Gastroenterol. 2015 Feb;110(2):328-35. doi: 10.1038/ajg.2014.398. Epub 2014 Dec 16. Erratum in: Am J Gastroenterol. 2015 Mar;110(3):480.

PMID:
25512338
3.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
4.

Safety and efficacy of low molecular weight heparin therapy during pregnancy: three year experience at a tertiary care center.

Singh N, Varshney P, Tripathi R, Mala YM, Tyagi S.

J Obstet Gynaecol India. 2013 Dec;63(6):373-7. doi: 10.1007/s13224-013-0412-4. Epub 2013 Jun 12.

5.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

6.

NOACs for thromboprophylaxis in medical patients.

Cohen AA, Rider T.

Best Pract Res Clin Haematol. 2013 Jun;26(2):183-90. doi: 10.1016/j.beha.2013.07.002. Epub 2013 Jul 21. Review.

PMID:
23953906
7.

[Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].

Arreola-Ornelas H, Rosado-Buzzo A, García-Mollinedo L, Dorantes Aguilar J, Muciño-Ortega E, Mould-Quevedo JF.

Cir Cir. 2012 Sep-Oct;80(5):411-8. Spanish.

PMID:
23351443
8.

[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].

Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Salud Publica. 2012 Dec;86(6):601-12. doi: 10.4321/S1135-57272012000600006. Spanish.

9.

Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.

Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N, Shibano T.

Thromb Res. 2012 Sep;130(3):514-9. doi: 10.1016/j.thromres.2012.05.008. Epub 2012 May 29.

PMID:
22647432
10.

Apixaban: a new player in the anticoagulant class.

Agrawal R, Jain P, Dikshit SN.

Curr Drug Targets. 2012 Jun;13(6):863-75. Review.

PMID:
22250655
11.

The role of apixaban for venous and arterial thromboembolic disease.

Prom R, Spinler SA.

Ann Pharmacother. 2011 Oct;45(10):1262-83. doi: 10.1345/aph.1Q119. Epub 2011 Sep 27. Review.

PMID:
21954450
12.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.

13.

Invited commentary.

Henke PK.

J Vasc Surg. 2010 Nov;52(5):1270-1. doi: 10.1016/j.jvs.2010.06.069. No abstract available.

14.

Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.

Zhang H, Löwenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP.

Blood. 2010 Nov 25;116(22):4684-92. doi: 10.1182/blood-2010-04-277798. Epub 2010 Aug 31.

15.

Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.

Kurtoglu M, Koksoy C, Hasan E, Akcalı Y, Karabay O, Filizcan U; TROMBOTEK Study Group.

J Vasc Surg. 2010 Nov;52(5):1262-70. doi: 10.1016/j.jvs.2010.06.070. Epub 2010 Aug 21.

16.

New options with dabigatran etexilate in anticoagulant therapy.

Maegdefessel L, Spin JM, Azuma J, Tsao PS.

Vasc Health Risk Manag. 2010 May 25;6:339-49. Review.

17.

Frequency of bleeding following invasive dental procedures in patients on low-molecular-weight heparin therapy.

Hong CH, Napeñas JJ, Brennan MT, Furney SL, Lockhart PB.

J Oral Maxillofac Surg. 2010 May;68(5):975-9. doi: 10.1016/j.joms.2009.09.054. Epub 2010 Feb 9.

PMID:
20144498
18.

Anticoagulation for cerebral venous thrombosis with subarachnoid hemorrhage: a case report.

Hegazi MO, Ahmed S, Sakr MG, Hassanien OA.

Med Princ Pract. 2010;19(1):73-5. doi: 10.1159/000252839. Epub 2009 Dec 9.

PMID:
19996624
19.

Life-threatening retroperitoneal bleeding due to warfarin-drug interactions.

Chan TY.

Pharmacoepidemiol Drug Saf. 2009 May;18(5):420-2. doi: 10.1002/pds.1729.

PMID:
19283775
20.

Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.

Narin C, Reyhanoglu H, Tülek B, Onoglu R, Ege E, Sarigül A, Yeniterzi M, Durmaz I.

Adv Ther. 2008 Jun;25(6):585-94. doi: 10.1007/s12325-008-0068-0.

PMID:
18568442
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk